Company News: Page (1) of 1 - 12/04/17 Email this story to a friend. email article Print this page (Article printing at page facebook

Updated larotrectinib pediatric Phase I clinical trial data demonstrates response in TRK fusion cancers

- 93 percent overall response rate of 17 pediatric patients with TRK fusion cancers- 94 percent of all pediatric patients remain on larotrectinib or received surgery with curative intent (December 04, 2017)
This article is no longer available,but here are some related topics.

Page: 1

Related Keywords:Pro AV,Management,Presentors,Business,Business Issues,Presentation,Corporate/Company,People,Events,USA, Inc.,Medicine,Disease,Surgery,Cancer,Surgery,Science,Environmental Technology,Green Technology,Medical,Biology,Genetics,Cancer,Business,Science,


Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved